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CHAPTER 1: INTRODUCTION
1.1

Breast Cancer Diagnostics
Cancer is a significant disease that has a major impact both in the United States and the

rest of the world. With over a million and increasing new cancer cases occurring yearly in the
United States, cancer will soon become the number one leading cause of death [1]. Nearly thirty
percent of all cancer cases in women alone is attributed to breast cancer [1]. Early, reliable disease
detection and diagnosis along with sufficient monitoring post treatment are paramount for
increased patient survival with breast cancer. Breast cancer, when detected in its localized stage –
stages 0, I, and II, provides the patient with a nearly 100% survival following treatment [2].
Regional breast cancer, stage III, provides a 85% five-year survival rate after treatment [2].
Therefore, enhanced early detection techniques with improved clarity and diagnosis can essentially
eradicate the disease that is present in tested individuals.
There are a variety of risk factors that can bring about breast cancer. Familial history of
breast cancer along with inherited modifications to the breast cancer attributed genes, such as
BRCA1, BRCA2, AKT2, CASP8, MAP3K1, and other related genes can significantly increase
risk of breast cancer [3]–[7]. Additionally, age is a contributing factor with a high increase of
breast cancer incidence occurring after the age of forty-five [2]. Obesity, dense breast tissue,
previous chest radiation, hormone replacement therapy, unnatural levels of estrogen, and
consumption of alcohol are other risk factors associated with breast cancer [6], [8]. There is a high
difficulty in deriving a method that can prevent breast cancer by simultaneously tackling all the
risk factors that can arise to it. Considering the success of breast cancer treatment when targeting
early-stage breast cancer, early detection methods are of great importance for defeating breast
cancer in its current state.
1

The majority of breast cancers originate from terminal ductal-lobular units. Mutation of
breast epithelial cells within the ducts or lobules form their respective carcinomas (ductal and
lobular carcinoma), and are diagnosed as stage 0 breast cancer. Local invasion of the carcinoma
denotes stage I breast cancer, with stage II breast cancer being attributed towards larger growth of
tumor nodules. Stage III breast cancer is a more progressed form than stage II, in which tumor
growths have increased mass from stage II and with regional spread of cancerous cells is observed.
Stage IV cancer indicates metastatic breast cancer where the malignant cells have spread to other
organs of the body, such as the individual’s bones, liver, brain, and lungs.
The current common methods of cancer detection are x-ray mammography, magnetic
resonance imaging (MRI), breast ultrasonography, and position emission tomography (PET).
Mammography is the most common and widespread method of breast imaging, utilizing low-dose
X-rays to exam breast tissue. Whilst mammograms have lowered mortality rates of women by
nearly one-third, it is extremely difficult to diagnose early stage breast cancer using this imaging
method on account of its high false-positive and false-negative rates [9]–[12]. MRI uses the
magnetic properties of the nucleus of hydrogen as its means of imaging. Due to the prevalence of
hydrogen in fat, water, and tissues, detailed images for any part of the body can be obtained through
MRI, especially when discriminating soft tissue from bone [9]. Regretfully, the limitations of MRI
includes slow scanning time, expensive to use, may not clearly make calcifications visible, may
lead to several false positives, and certain contrast agents can induce kidney problems or
hyperthermia in patients [9], [13]. Breast ultrasonography provides improved cancer detection
within denser breast tissue in which mammograms suffer in providing accurate data, yet breast
ultrasonography suffers the same issue that breast mammography does regarding its low spatial
resolution [14], [15]. PET is a three-dimensional imaging technique that detects γ rays emitted
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from external radionuclides that is injected into the body. PET is able to see the differences
between normal and cancerous cells based on their metabolic activity [9]. However, PET subjects
the patient to high random radiation exposure and it is quite expensive whilst also suffering from
poor resolution images [16], [17].
If clarification of the suspect tissue cannot be resolutely confirmed through the sole usage
of imaging diagnostics, tissue extraction and analysis is appended to the diagnostic procedures, as
seen through histology. Tissue analysis is completed based on the morphological characteristics
of the tissue sample, which is due to chemical changes and interactions within the specimen. This
analysis brings out accurate observations of the tissue sample, providing a concrete validation if
the sample is cancerous or benign. Cancer is a disease that is derived from a multitude of factors
in which spectroscopic techniques must be able to discriminate from, thus establishing the different
stages of pathogenesis and their underlying mechanisms. Definitive biomarkers came about as a
response to this need, thus allowing monitoring of the pathways regarding receptor expression,
signal transduction, cellular metabolism and proliferation [9], [18], [19]. Due to the reliance of
contrast in analyzing data from images provided by imaging systems, external agents are generally
needed for external labeling [20]. External agents focused on these biomarkers help target and
increase contrast in these areas of interest thereby providing the suitable environment for imaging
systems. However, it would be highly desirable to achieve a method that can provide the sensitivity
and specificity of histological analysis, without any labeling agents. This would allow a procedure
to have on-site detailed analysis without any specific facilities for tissue extraction, labeling, and
analysis. Therefore, having a mechanism for label-free diagnosis is highly desirable and a means
to achieving this objective has presented itself: Optical diagnostics.

3

1.2

Breast Optical Imaging Diagnostics: A Brief History
Advances in medical optical imaging techniques realized a novel idea of utilizing optical

techniques for breast cancer diagnosis. In 1929, Dr. Max Cutler suggested that breast tissue may
have its own unique optical properties that can differentiate between normal and cancerous cells
[21]. Cutler developed a method titled ‘transillumination’ by which light originating from a
powerful emission source penetrates through breast tissue and the projected is observed. The
projected image allows for basic visualization of potential lesions, thus giving the observer a
rudimentary understanding of the breast’s situation. However, complications such as overillumination, unable to identify deep lesions, and failure to discriminate benign cysts from proper
tumors were but a few drawbacks from this technique.
Nearly forty years later, in 1970, technological advances in film and cameras renewed
interest in transillumination, which became commonly known as diaphanography techniques.
Pulses of visible and near-infrared light are sent through the breast and is registered by a video
camera [22]. Multiple different perspectives are used in this diaphanography technique as a means
to survey the breast from all possible angles. The obtained data from the video camera is
algorithmically transformed and composited to form a desired response. A massive drawback was
excessive light scattering resulting in a large amount of light absorption within the breast tissue
[22], [23]. The light absorption from the emission source prevented accurate detection of deep
lesions. Additionally, due to the visual nature of the technique and reliance on the technical
expertise from the operator, this technique was highly prone to error.
A couple decades following the improvements in video camera technology in the early
1990’s, the natural progression of technology brought about sophisticated approaches towards
optical breast cancer detection. Frequency domain imaging was one major innovation regarding
4

diaphanography techniques. Frequency domain imaging sought to improve the difficulty
diaphanography has in overcoming excess light scattering in breast tissue by utilizing near-infrared
light whose properties exhibit enhance penetrance in organic matter. Near-infrared light is highly
sensitive towards oxygen attributed species, such as hemoglobin, water, and general oxidation of
tissues [24]. Due to significant oxygenation changes coupled with breast tumor formation, nearinfrared light became a standard in optical mammography during this period [25], [26].
Taking near-infrared absorption as the foundation for optical mammography, increased
focus was directed towards determining the absorption and scattering variables of emitted light
through the breast [26]. Frequency domain imaging provided a means of determining a reference
to these coefficients by focusing on transmission of photons from narrow-beam transillumination
rasterization of the breast tissue utilizing frequency domain algorithms. This method allowed the
obtained signal to disregard the photon’s path length within the breast, therefore allowing all
emitted photons being contributed towards workable data [27]. The obtained signal consists of
harmonic components that can be effortlessly decomposed into lower frequency components
without any substantial data loss [27]. “Edge-corrected” optical mammograms, commonly known
as N-images, provide the enhancements in contrast from diaphanography images. The two
components derived from frequency domain imaging, the phase and amplitude of the signal, are
reconstructed after processing to provide information about breast thickness and oxidation
properties. The N-image construction algorithm is defined as the following:

Equation 1.1: N-image construction algorithm
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Where N is the N-coefficient, x and y indicate the pixel coordinates from image scanning, r0 defines
the separation of plates around the breast, ac0 is the amplitude where breast is at thickness r0,
ac(x,y) is the amplitude at pixel coordinates and lastly r(x,y) is thickness of breast at pixel that was
derived from the phase information. The outcome of this technique allowed for significant
improvements regarding discrimination of tumor detection and overall image contrast and quality
in comparison to traditional diaphanography [25], [27]. Despite the penetrance properties of nearIR wavelengths in organic tissue, the scattering and absorption of the emission source still has
significant influence on both phase and amplitude signals measured from the sample [27]–[29].
As a consequence of this influence, the analysis of the low frequency components may still yield
false positive and negative outcomes - higher contrast results are achieved but are not foolproof.
Advancing towards the era of modern breast cancer imaging, tomography has a noteworthy
entrance. With near-infrared wavelengths having a growing traction in the field of optical
mammography, tomographic systems were able to exhibit their full potential. The average
wavelength collection range for topographies are generally between 650 to 830 nm, operating from
two to four separate wavelengths. Tomography methods observed concentrations of molecular
species from the sample through separation of scattering and absorption coefficients. There is an
observable high amount of photon scattering within this range, but the advantages of being
sensitive to water, oxy-hemoglobin, deoxy-hemoglobin, and general lipids overcome the initial
scattering disadvantage [30]. Tomography methods, enhanced by diffuse approximation, allow
visualization of these prominent chromophores and provide detailed characterization and detection
of breast cancer. However, limitations of excess scattering, increase in blood attenuation at sub650 nm wavelengths, and limitations of commercial detectors at above 900 nm cause
complications in accuracy regarding signal levels.

6

Raman spectroscopy is an optical microscopy technique that can potentially remove most
of the complications that other techniques exhibit, whilst providing an excellent source of
information to analyze data at hand. This technique originated in early 1928, where Sir
Chandrasekhara Venkata Raman discovered inelastic scattering, which served as the foundation
of the Raman effect. Sir Raman discovered this phenomenon through the crude mechanism of
using the sun as his light source and his eyes as his detector. During a sea voyage Sir Raman
wanted to discover the reason for the blue color that was emitted by the ocean. Sir Raman could
not accept that this blue color was strictly due to the sky’s reflection onto the water’s surface and
so, by procuring a quartz prism from his person, he was able to determine that there was indeed a
discrepancy between the color emitted from the water’s surface and that from the sky above.
Immediately upon returning to his homeland, he went out to recreate this phenomenon and to
observe the mechanisms behind this ‘molecular diffraction’ as Sir Raman labeled it at the time.
Through several experiments, purification of numerous solids and liquids and the arrangement of
a wide array of different lamp excitation sources, Sir Raman was able to prove and present his
findings on ‘modified scattering’ which later became the technique to bear his name: Raman effect.
Raman scattering gained a huge attraction after its world-wide introduction in the 1930s.
the majority of early Raman observations were conducted with the observer’s eye as the main
detector. The main crux of Raman scattering was the need for improved conditions to observe
Raman scattering more easily, due to the nature of only one in ten million photons will exhibit the
inelastic scattering that brings about the Raman effect. Therefore, two major areas in Raman
spectroscopy sought improvement: the presence of a strong excitation source and improvement of
the base sample. A strong excitation source was desired as a means to increase the rate in which
Raman scattering occurred. Due to the inherit weakness of the Raman effect, samples were heavily

7

purified to limit the probability that a Raman signal was attributed to the impurities present in the
sample.
1.3

Early Biological Identification and Applications
Raman spectroscopy gives detailed analysis of biological compounds through defined

vibrational peaks. Raman’s vibrational peaks provide association characteristics to lipids, proteins,
nucleic acids, and carbohydrates, giving rise to a fingerprint unique to the particular sample being
analyzed. Cancerous and noncancerous cells have discrete morphological characteristics due to
chemical composition of their biological constituents. As such, vibrational peaks given by Raman
spectroscopy dictate these modifications between the biological compounds and provides different
overall spectrums for cancer and noncancerous tissues and cells. Raman spectroscopy has the
ability to freely choose excitation wavelengths that avoid water absorption bands, a serious
requirement for in vivo and living tissue assays. Raman spectroscopy has a clear advantage over
other optical spectroscopic techniques by providing real-time direct investigation of biological
constituents within a label-free environment.
The advantages of Raman spectroscopy, through its sample chemical composition
identification along with water having a minuscule impact on the observed spectrum, naturally
lead Raman spectroscopy into the field of biological analysis. Raman spectroscopy has been
applied towards plant tissue analytics, mammalian tissue diagnostics, macromolecule breakdowns,
molecular bond chemistry, and other biological constituents [31]–[35]. Raman spectroscopy has
been considered for usage in medical applications as early as 1988 [36]. Raman spectra obtained
from biological materials are quite complex, as the spectra depicts all the biological constituents
from the sample in the measured location. Raman spectroscopy entered the field of breast cancer
diagnostics in the early 1990’s [37].
8

1.4

Label-Free Raman Spectroscopy in Breast Cancer
Label-free Raman spectroscopy has been used towards breast cancer with great success.

The ability to differentiate benign from malignant lesions has been completed in the early 2000’s,
attaining results of nearly 95% for both sensitivity and specificity in the analysis [38], [39].
Furthermore, profiling of Raman bands through the usage of principal component analysis and
multivariant analysis provides a clear distinction between benign and malignant lesions [38]–[40].
However, one important factor to note is that despite benign and malignant discrimination can be
effectively done through label-free means, the exact chemical modifications in the observed
molecule targets are difficult to discern to the point of being potentially undetectable [38], [40].
Haka et al. approached this challenge by developing a macroscopic tissue spectra model for breast
tissue. This model provided a reasonably accurate breakdown of biological constituent
concentrations in breast cells and tissue, including the cell’s nucleus and cytoplasm, collagen,
calcium derivatives, and lipid deposits [38]. Other groups also focused on deconvolution of Raman
spectra, providing an understanding of present biological constituents, such as lipids, DNA, and
proteins, with their related intensities [41].
Despite having a very detailed understanding of macromolecule concentrations and
intensities in breast cells, label-free diagnosis of the instigator behind breast cancer has yet to be
fully achieved. This is due to biological targets, such as p27, MAPK, and epidermal growth factor
receptors, being present in nanomolar concentrations which is below the label-free Raman
spectroscopic detection limit [42].
Detection of nanomolar concentrations can be achieved by Raman spectroscopy through
the usage of tagging agents. One such method is surface enhanced Raman spectroscopy in which
metallic nanoparticles such as gold, silver, quantum dots, and gelatin particles are used in tagging
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the desired analytes [43]–[45]. The nanoparticles are developed with specific attachments that
show high affinity for the analyte of interest. Once the nanoparticles are distributed in the desired
location, activity complexes will form between the nanoparticles and their targets. Plasmon
resonance and chemical enhancement can be observed, resulting in an enhancement of the Raman
signal [43], [46]. However, surface enhanced Raman spectroscopy is not possible without the
usage of tagging agents, and as such it is beyond the scope of this paper.
1.5

Epidermal Growth Factor Receptor Breast Cancer Optical Imaging Targets
Twenty-five to thirty percent of breast cancer is related to HER2/neu oncogene

amplification [47]–[49]. HER2 is a member of the transmembrane Epidermal Growth Factor
Receptor (EGFR) type I family which also encompasses EGFR(HER1), HER3, and HER4
receptors [50]. EGFR, also known as HER1 and ErbB-1, contains a function intracytoplasmic
tyrosine kinase domain and accessible extracellular ligand binding region. EGFR is also responsive
to a host of ligands, including EGF, HB-EGF, TGF-α, amphiregulin, epiregulin, betacellulin, and
epigen [51]. HER2 lacks an accessible ligand binding region and as such, it is unable to respond
to extracellular signals by itself. However, HER2 contains a fully functional tyrosine kinase
domain and is able to initiate the signal transduction EGFR pathway. HER3 is the opposite of
HER2, where it has no functional tyrosine kinase domain, but has a limited ligand binding region
that is responsive towards NRG1 and NRG2 ligands [52], [53]. The final member of the family,
HER4, is similar to HER1 in which it has both a tyrosine kinase domain and an accessible ligand
binding region, but differs in responding only to neuregulin-class ligands and it is generally present
at lower quantities and influence than HER1.
Overexpression of HER1 and HER2 is a prime indicator of carcinogenesis of breast cancer
cells due to HER2’s special characteristic of always being present in an open dimer configuration
10

[54]. Despite there being a total of ten different combinations of the dimerization possible within
the EGFR family, there’s only a small subset within the combinations that actually have biological
importance [55]. Within this subset, it is HER2’s open dimer configuration that makes it the
preferred dimerization partner within the EGFR family, and thus has the most prominent influence
[54]. When HER2 creates a dimer complex with another family receptor, HER2 causes a
significant amplification of the signal cascade originating from the dimerized receptor. Therefore,
in EGFR family related cancer, considering HER1’s fully functional and high-influence signal
cascade when combined with HER2’s signal amplification, overexpression of the
heterodimerization of the two receptors gives rise to predominant type of EGFR breast cancer.
The major pathways of interest in EGFR activation are phosphatidylinositol 3-kinase
(PI3K) with associated protein kinase B (Akt), mitogen-activated protein kinase (p44/42 MAPK),
and a regulator of the cell division cycle, the p27 protein. These pathways are briefly explained in
the following subsections. The PI3K/Akt pathway is related to a significant amount of cellular
processes including proliferation, differentiation, cell growth, cell survival, and intracellular
molecular trafficking. The P13K family has four different classes within, however it is the PIK3CA
(p110α) related gene that is found mutated within cancers. This gene codes for a catalytic P13K
kinase, in which cancer mutation results in excessive kinase activity. This activity is not exclusive
to breast cancer alone, but it is important to note its relationship with EGFR family. EGFR is
located directly upstream of the P13K kinase, therefore overexpression of EGFR directly targets
and enhances the level of kinase activity from the P13K kinase [56]–[58].
The MAPK/Ras/Raf pathway begins with the activation of EGFR, triggering a
phosphorylation event on the intracellular tyrosine kinase domain. The activity in the tyrosine
kinase domain causes activation of the guanine nucleotide exchange factor SOS through docking
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protein intermediaries, such as GRB2 [59]. SOS activation stimulates GDP removal from GDPRAS proteins, promoting GTP-RAS formation. The now activated RAS protein (in the form of
GTP-RAS) activates RAF kinase, a serine/threonine protein kinase, thereby allowing
phosphorylation of MEK1 and MEK2, a pair of serine/tyrosine/threonine kinases [60]. MEK1 and
MEK2 can then phosphorylate and activate the mitogen-activated protein kinase MAPK, a
serine/threonine protein kinase, which then leads to phosphorylation events of nuclear influencing
proteins which result in tumorigenic activity when unregulated [55].
The p27 related pathway is another region of interest due to the cell proliferation
regulation ability of p27 itself. The p27 protein serves as a cell proliferation inhibitor by
preventing the cell cycle from progressing through the G1 phase into the S phase. Inactivation
and degradation of p27 prevents arrest of the G1 phase, therefore allowing the cell to proliferate
uncontrollably. Overexpression of the EGFR family accelerates p27 proteolysis due to
concomitant pathways inducing p27 polyubiquitination [61]. EGFR can also bind to c-SRC, a
non-receptor tyrosine kinase, activating its respective pathway that induces p27 degradation
when overexpressed [61]–[63]. EGFR overexpression of Rho- and MAPK-dependent
mechanisms can facilitate p27 proteolysis through a Ras intermediary [61], [64]. EGFR
amplified pathways may also translocate p27 out from the nucleus and into the cytoplasm [61],
[65]. Mislocalization of p27 retains the normal quantity of p27 as seen in non-cancerous cells,
yet none of p27’s tumor suppressing effects are active [61]. Therapies that target the preservation
of p27 have been recorded to cure, or substantially alleviate, EGFR/HER2 amplified cancers
[66]–[68].
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CHAPTER 2: INTRODUCTION TO SPECTROSCOPIC METHODS
Spectroscopy is the study of the interaction between electromagnetic radiation and
matter. Electromagnetic radiation is a form of energy where the properties can be explained
in both waves and particles. There are a multitude of techniques that observe these
interactions and properties and collect the information into data known as a spectrum, or
spectral data. Some of these techniques are Raman Spectroscopy, Fourier transform infrared
spectroscopy (FTIR), Mossbauer spectroscopy, atomic absorption spectroscopy (AAS) and Xray spectroscopy. Each technique obtains spectra information from a different perspective,
therefore no single technique is able to provide detailed information of a sample in its entirety.
It is common to use a combination of techniques to provide a complete picture, and certain
sets complement each other significantly more than other sets. Raman and FTIR is one
example of complimenting techniques that provide different perspectives on the same
property: vibrational modes of a sample. Raman spectroscopy observes inelastic photon
collisions which provides information on symmetrical vibrational modes. FTIR measures
interaction between the material and infrared emission, complimenting Raman spectroscopy
by giving insights to non-symmetrical vibrational modes.
Materials have unique vibrational modes that formulate a fingerprint identification
that is specific to that material alone. In the case of inhomogeneous materials, the constituents
have their own unique vibrational modes that can be analyzed as a part of a whole.
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2.1

Raman Spectroscopy
Sir Chandrasekhara Venkata Raman discovered a phenomenon with the scattering of

light in 1928, which is now known as the Raman Effect. Raman discovered that not all light
deflects with a uniform wavelength after encountering a material – instead a small percentage of
light will have a change in wavelength after deflection. This change in wavelength is due to
the inelastic scattering of photons following deflection. If the incidence photon gives off its
energy to the contact material, Stokes Raman scattering occurs. If the opposite is observed,
where the material loses energy and the incidence photon gains it upon scattering, this is
known as anti-Stokes Raman scattering. The occurrence of inelastic scattering is quite rare, at
an average of ≈ 10-6 photons undergoing the observable effect. However, when there is no
modification in wavelength after deflection, elastic scattering occurs which is known as
Rayleigh scattering. These observations provided the foundation of Raman spectroscopy.
2.1.1 Classical Description
Consider a molecule that does not have a permanent dipole moment containing a
positively charged nucleus that is surrounded by a negatively charged group of electrons.
Electromagnetic radiation interacts with the molecule, an oscillating electric field is produced.
The electric field induced by the electromagnetic radiation is as follows:

Equation 2.1: electric field induced by electromagnetic radiation

Where 𝐸0 is the maximum amplitude of the electric field with a dependence on the frequency of
the electric field 𝑣0 at time 𝑡 of incidence of the electromagnetic radiation interaction with the
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molecule. The electric field will induce a dipole moment in the molecule which can be described
as:

Equation 2.2: Electric field induced dipole moment

Where µ is the dipole moment, α is the polarization of the molecule, E0 is the
maximum amplitude of the electric field with a dependence on ωL. Molecules generally
exhibit asymmetry geometry thereby causing the dipole moment µ to no longer be
parallel with electric field E. As such, α is the polarizability tensor of the molecule.
The components of the dipole moment µ due to the polarizability tensor α can be
written as:

Equation 2.3: Polarizability tensor dipole moment components

The polarization of the molecule is also related to the molecule’s vibration. α,
being the polarizability tensor, therefore depends on the vibrational coordinate Q, which
in return depends on the molecular vibrational angular frequency ωM, as shown:

Equation 2.4: Vibrational coordinate due to molecular vibrational angular frequency

Therefore, the Raman frequency components can be obtained through the amplitude
modulation, which is due to the change in polarizability. The variability in polarization can
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be easier understood with the implementation of the Taylor series expansion for the
polarizability:

Equation 2.5: Taylor series expansion for polarizability

Inserting the Taylor series expansion (Eq. 2.5) and the vibrational coordinate Q equation (Eq. 2.4)
into the induced dipole equation (Eq. 2.2) allows for the following first-order expression to be
obtained:

Equation 2.6: First-order induced dipole moment

We can observe three components of the finalized first-order induced dipole moment
equation. The first term, [ α0 E0 cos (ωL t)], accounts for no changes in frequency between the
scattered light and the incident light, describing what is known as Rayleigh scattering, or
elastic scattering. The second term, [cos ((ωL − ωM ) t)], accounts for inelastic scattering
where the incident photon loses its energy after deflection, also known as Stokes scattering.
The third term, [cos ((ωL + ωM ) t)], accounts for the other form of inelastic scattering, where
the photon gains energy following deflection, and is known as anti-Stokes scattering.
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2.1.2 Quantum Approach

Figure 2.1: Energy level diagram for Raman scattering.
(a) Stokes Raman scattering (b) anti-Stokes Raman scattering [92].

Within a material, there are a multitude of structures available – whether they are simply
molecular structures, lattice structures, or general chemical functional groups. A scattered photon
that comes within contact of a material’s structure will interact with said structure, generally in
terms of energy transfer and deflection. During a photon’s collision with a structure, a transfer of
energy to the structure occurs. This will excite the structure into a virtual quantum state. The
structure will return to ground state and re-emit the photon. The re-emitted photon will either
have a difference in the energy it had prior to collision, or it will have the same energy from prior
to collision. If no changes in energy is observed, the photon’s wavelength does not have
modification and thus elastic scattering, or Rayleigh scattering, occurs. However, if the structure
returns to its ground state and re-emits the photon with less energy from before, the photon will
have a change in wavelength, thereby lowering its frequency and increasing its wavelength. This
change is miniscule, often within the order of a few wavenumbers (cm-1). If the structure has
higher energy than the photon prior to collision, the structure will re-emit the photon with higher
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energy, and thus a higher frequency. Observing the spectrum, if the emitted photon has lower
energy spectral lines, they are called Stokes spectral lines. In relation, if higher energy spectral
lines are observed, they are called Anti-Stokes lines.
2.2

Confocal Raman Spectroscopy
Raman spectroscopy provides several advantages in the world of microscopic analysis

from observations obtained from its scattering technique. However, early implementations of the
Raman spectroscopic technique suffered slight drawbacks due to its scattering nature. With
conventional wide-field microscopy, high resolution imaging was difficult due to the excessive
amounts of scattered light. Conventional wide-field microscopy illuminates the entire sample,
bringing rise to a numerous amount of scattered light, blurring the overall image. Not only would
this cause a blurring in the visual image observed, but this also directly affects the efficacy of the
Raman spectroscopic technique applied to the sample. Therefore, a solution was investigated by
Professor Marvin Minsky to circumvent this hindrance and provide a new path in high-resolution
microscopy [69], [70].
The limitations of wide-field microscopy were overcome in 1957 through Professor
Minsky’s patenting of confocal imaging. The first steps in confocal microscopy arose with the
ideology of focusing on each point of a specimen at a time, instead of viewing the full sample at
once. Placement of a small aperture in front of the initial illumination source focuses the
illumination onto a singular point upon the sample. Just this small application has the ability to
lower the overall amount of scattered light by an appreciable amount whilst improving overall
image quality. Whilst this method eliminates the majority of excess light scattering from the
illumination source, it does not take in account the excess scattering derived from light reflection
off of the sample surface. Elimination of excess surface scattering can be achieved by the
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application of a second pinhole aperture located between the image plane and the microscope
objective. The second aperture has a secondary effect regarding the manipulation of the depth of
field from the sample. In this design, not only is scattered light from out-of-focus points gets
discarded, but it also provides the means to obtain a Z-series from the sample. A simplified diagram
depicting the process can be observed in Figure 2.2, where the optional filters indicate the locations
of the pinhole apertures described previously. The quality difference between conventional widefield microscopy and confocal microscopy can be readily observed in Figure 2.3.

Figure 2.2: Simple Raman confocal microscope diagram
Figure obtained from R. S. Das and Y. K. Agrawal [93].
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Figure 2.3: Image comparison between wide-field microscopy and confocal microscopy.
(a-c) is attributed towards conventional wide-field microscopy and (d-f) is obtained from confocal
microscopy Samples used for comparison are: Human medulla (a, d); Rabbit muscle fibers (b, e);
Sunflower pollen grain (c, f) [94].

Confocal microscopy allows for significant improvements in image fidelity, but the very
nature of the technique has a draw-back in comparison to wide-field microscopy. Due to the image
acquisition being focused on a singular point, an entire mapping of the sample is required to
provide a complete image. Initially, when Professor Minsky worked out a method to map the entire
sample, it was focused on keeping the laser and microscope instruments stationary whilst moving
the stage. This method allowed for a stable and accurate confocal microscopy setup focused on a
singular point. Unfortunately, the physical movement of the stage could affect delicate samples,
such as organic matter, causing the finalized image to be slightly blurry or misaligned. Advances
in confocal microscopy opted for the approach of keeping the sample stage stationary with the
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laser having the movable characteristics. A purely stationary sample removed motion induced
blurring, but at the cost of more sophisticated optical systems to eliminate potential lens
misalignment imperfections.
Raman spectroscopy, when coupled with confocal microscopy, provides excellent data
harvesting from a sample. With this system, confocal microscopy provides a point-by-point
mapping of the sample in an X-Y-Z data cube model. Each point of this model will have its own
unique Raman spectrum associated from it, created at the time of scan integration. The final result
is a confocal Raman spectra data set consisting of X-Y-Z data points, where each X-Y pair has its
respected Raman spectrum projected in the Z-axis. This data provides excellent visualization of
the sample’s Raman spectrum in a 3D environment, allowing multiple perspectives and approaches
to a sample’s Raman spectrum, which is expanded later in Chapter 3.
2.3

Raman Spectrum and Molecular Vibrational Modes
A Raman spectrum is composed of Raman peaks that are dictated by the vibrational modes

of a molecule that are derived from the rotational and stretching modes of a molecule. The Raman
spectrum consists of a centered point around the wavelength of the initial excitation source, with
increasing or decreasing wavenumbers extending from that point as per the experimental setup.
The conversion from the observed spectral wavelength to wavenumbers utilized in a Raman
spectrum can be observed in the following formula:

Equation 2.7: Wavelength to wavenumber conversion
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Where Δν is the Raman wavenumber converted from spectral wavelength, 𝜆0 is the excitation
wavelength, and 𝜆0 is the wavelength from the inelastic scattering formed by the Raman effect.
When elastic scattering is observed, the values of 𝜆0 and 𝜆1 cancel out, providing a net Δν value
of zero, thereby eliminating its contribution to the Raman spectrum. Wavenumbers that follow an
increased positivity in value are generated by stokes scattering. Wavenumbers that follow the
opposite trend, in which an increase in the negative domain is observed, are generated by antistokes scattering. The stokes and anti-stokes Raman peaks that are recorded are red and blue shifted
respectively.
The number and intensity of Raman peaks that are observed in a Raman spectrum are
always dependent to the number of vibrational modes in a sample. However, not all vibrational
modes are represented in the Raman spectrum. This may be due to the vibrational modes not being
activated by Raman scattering, or modes exhibiting identical vibrational responses in the presence
of the excitation wavelength. Vibrational modes observe a mirror effect around the excitation laser
point, where stokes and anti-stokes scattering will exhibit identical displacement from the origin.
Additionally, the intensity in Raman peaks formed by anti-stokes scattering will be lower in
magnitude in comparison to stokes-scattering, due to the lessened frequency of occurrence.
Vibrational modes in a molecule can be quantified by the measure of atoms within that
molecule. By extension, the amount of vibrational modes in a biological sample is reliant on the
quantity of its molecular constituents and their respectful atom counts. Molecules are limited by
3N degrees of freedom, a description bounding the molecule in relation to each of three
dimensional Cartesian axes. Furthermore, a molecule is limited in two states, linear or nonlinear,
depending on its symmetry around the molecular axis. Therefore, a visualization of each
molecule’s degree of freedom can be observed in Table 2.1.
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Table 2.1. Degrees of Freedom in Linear and Nonlinear Molecules
Total
Degrees
Freedom

of Translational
Degrees of Freedom

Rotational Degrees
of Freedom

Linear Molecules

3N

3

2

Nonlinear Molecules

3N

3

3

The number of atoms present in a molecule is represented by N. By obtaining the total
degrees of freedom in a molecule, and applying the constraints provided by the translational and
rotational degrees of freedom, the remaining degrees of freedom will be the vibrational degrees of
freedom. Linear molecules, such as carbon dioxide (O=C=O) and acetylene (H-C≡C-H), have no
displacement of nuclei upon rotation around the molecular axis, therefore this rotation is not
considered to be a limit of freedom. The formulas for obtaining the vibrational degrees of freedom
in linear and non-linear molecules are as follows:

Equation 2.8: Degrees of freedom in linear molecules

Equation 2.9: Degrees of freedom in non-linear molecules

Where N is the quantity of atoms in a molecule and νn are the vibrational degrees of freedom. The
vibrational degrees of freedom are directly related to the vibrational modes observed as Raman
peaks in a Raman spectrum.
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2.4

Raman Spectra Analysis

2.4.1 Fluorescence Interference
The background fluorescence that arises during Raman spectroscopy is a huge impediment
on the final spectrum. It is important to not confuse fluorescence with Raman scattering, as the
difference between the two is quite substantial. Unlike Raman scattering, the incidence photon in
fluorescence is completely absorbed by the entire molecule, while it is instead scattered or
‘bounced off’ in Raman spectroscopy. The absorbed photon in fluorescence increases the overall
molecule’s energy state to a higher level. The fluorescent photon is then released when the
molecule achieves a lower energy state. The fluorescence released lasts over a period of time,
several nanoseconds, whereas the scattered photon in Raman scattering occurs instantly.
In highly excitable samples, the fluorescent background can completely eclipse the Raman
spectrum, resulting in invalid data. It is important to limit the influence fluorescence interference
to expose the underlying Raman spectrum. One particular method of limiting fluorescence is
specific selection of the excitation wavelength. Laser excitation wavelengths near infrared (NIR)
and ultraviolet (UV) wavelengths tend to show very low to nonexistent fluorescence. The
reasoning behind this is twofold. For NIR wavelengths, the excitation photon does not have enough
energy for the molecule to exhibit fluorescence. For UV wavelengths, the fluorescence will be far
removed from the Raman spectrum itself, therefore no true interference is observed. The
drawbacks of far-ranged wavelengths are the limit of sensitivity on detectors. Despite no
fluorescence observed, the recorded signal would be negligible in general providing nonvaluable
data.
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2.4.2 Post-Experimental Fluorescence Elimination
Most fluorescence interference is generally eliminated, or reduced, through postexperimental methods. Background subtraction is the most prominent method, in which the
fluorescent background is separated from the Raman spectrum, leaving the resulting Raman
spectrum easier to observe. This method takes advantage of the characteristics of fluorescence,
where fluorescence exhibits a much larger temporal domain than Raman scattering, and the band
response is very broad compared to the Raman band response. By utilizing a high enough
polynomial fitting that will account for the changes in fluorescence, a suitable analog to the
fluorescence structure can be obtained. Subtraction of the analog from the Raman spectrum will
preserve the sharper Raman peaks and eliminate the fluorescence background. Figure 3.1 depicts
a before and after example of background subtraction on a Raman spectrum. Specified points
depicting fluorescence contributions are selected with orange circles, where a moving polynomial
fit is applied as seen in Figure 3.1A. The underlying background that is selected is a similar match
to the fluorescent background, and thereby removal of the background results in a clean Raman
spectrum as seen in Figure 3.1B.
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Figure 2.4: Raman spectrum before and after background subtraction
(A) Raman spectrum with fluorescent background. Polynomial background curve indicated in
orange. Polynomial discrimination points indicated with orange circles. (B) Raman spectrum
after background subtraction. Over-prediction subtraction occurred around the 250 cm-1
vibration, due to influence of the plasma line. However, this subtraction does not influence the
final data, as the low-range wavenumbers are contributed by the fixing agent for this sample.
Another method of background subtraction is the opposite of the previous method, in which
the traditional characteristics of Raman peaks are used against the fluorescence background. In
this method, the discrimination bias is towards sharper bands resembling Raman responses and
against the wider fluorescent bands. Once the pattern recognition is completed, the algorithm can
essentially ‘pull down’ the preserved bands to the baseline, discarding the fluorescent background
concurrently.
Aside from polynomial fitting techniques, fast Fourier transforms can also be utilized for
background subtraction. Fourier transforming the spectra will provide a frequency domain
separation of fluorescence from Raman responses. The lower frequency population will be
attributed to the fluorescence response, whereas the higher frequency population will belong to the
sharper, Raman responses. A high pass filter can be applied to discard the lower frequency
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population whilst retaining the higher frequencies. Application of inverse fast Fourier transform
will provide the final Raman spectrum with the fluorescent background absent.
2.5

Raman Spectra Visualization
Raman spectroscopy provides not only a label-free, non-invasive means of molecule

identification, but can depict a visual representation of Raman intensity distribution. Confocal
Raman microscopy (CRM), a microscopy technique described in the previous chapter, provides
the mechanism for Raman spectra visualization. CRM scans over a sample within specified
boundaries, obtaining a Raman spectrum for each scanned point. The final series of spectra can be
remolded, creating a visualization of both the specimen and the related Raman activity. The
advantage of spectra visualization is the ability to observe emergent properties from the visual
distribution of Raman activities.
Figure 2.5 shows an example of combining background subtraction and spectra
visualization. The sample presented is a low-fluorescent, MCF-7 breast cancer cell, with a focus
on the 1240 cm-1 band, which is attributed to amide III content in proteins [71]. Figure 2.5A depicts
a confocal Raman measurement of the cell without any background subtraction. Despite the cell
having low-florescence, the resulting Raman spectra is still quite noisy. Figure 2.5B is the visual
spectra after background identification and subtraction is executed. There is a much higher
distinction between high activity areas and low activity areas, which was not present before.
Through manipulation of exposure values, one can obtain the result in figure 3.2C. In figure 2.5C,
the intensity of the amine III vibration is easy to perceive in the MCF-7 cancer cell.
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Figure 2.5. Raman background subtraction and spectra visualization on MCF-7 Cancer Cell.

(A) Raman activity visualization of MCF-7 cancer cell at 1240 cm-1 band. No background subtraction applied.
(B) Background subtraction applied to original activity spectra. (C) Exposure values modified from [B], providing
higher distinction of 1240 cm-1 band distribution in cell. Visualization and background subtracted was conducted
in MATLAB r2016a.
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2.5

Experimental Setup
For this study, specific configurations for software, hardware, and cells were used based

on the available accommodations.
2.5.1 Control Sample Preparations
MCF-10A (non-tumorigenic breast epithelial cells, control sample) and MCF-7
(tumorigenic, control sample) human breast cancer cell lines were grown under identical
conditions in RPMI media, supplemented with 10 % heat-inactivated fetal bovine serum, 100 U/ml
penicillin and 100-μg/ml streptomycin. Plain microscope slides coated with Poly-L-lysine were
used to grow 500,000 cells over an 8-hour period. After the 8-hour incubation period, cells were
washed with 1X PBS- three times and flooded with 4% paraformaldehyde to fix cells for 1 hour
at room temperature. After the 1 hour incubation, the samples were again washed three times with
1X PBS and then allowed to air dry for 15 minutes at room temperature.
2.5.2 Western Blotting Configuration
Cells were grown to ∼90% confluency in normal culture conditions and starved in serum
free media for 24 hours prior to EGF addition. After 24 hours, the control cells were left in serum
free media whilst the experimental cells were treated with 100 ng/ml of EGF for 30 minutes. All
cells were washed afterwards with ice-cold PBS and detached from plates by trypsin (0.25% wt/vfrom Hyclone). Cells were centrifuged for 5 minutes at 1200 rpm. The cell pellets were then
resuspended in different cold lysis buffers; RIPA-like [20 mmol/L Tris (pH 7.5) containing 137
mmol/L NaCl, 100 mmol/L NaF, 10% glycerol, 1% NP40, 2 mmol/L Na3VO4, 1 mmol/L
phenylmethylsulfonyl fluoride, 10 μg/mL aprotinin, and 10 μg/mL leupeptin], NP-40 [20 mmol/L
Tris (pH 8), 137 mmol/L NaCl, 10% glycerol, 1% NP-40, 2mmol/L EDTA], and Milliplex Map
Lysis Buffer (Biellerica, MA).
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Resuspended cell pellets were then incubated on ice for 10 minutes, and cleared by
centrifugation. Protein concentrations of the supernatant were determined using Bio-Rad Protein
Assay Dye Reagent (Bio-Rad Laboratories). Samples were resolved on 8-12% SDS-PAGE (30 mg
of lysate per lane) and then transferred onto Immobilon-P membranes (Millipore). The membranes
were blocked in 10% milk in TBST for 1 h at room temperature. Next, the primary antibodies antiphospho Akt (Ser473) and anti-phospho p44/42 MAPK (Thr202/Tyr204) (Cell Signaling
Technology, Massachusetts-1:1000 dilutions) were added and incubated overnight at 4 °C.
membranes were then washed several times in TBST and secondary antibodies (1:5000 dilution)
were added for 1 hour at room temperature, and then washed again 5 times in TBST (5 minute per
wash) prior to detection using the ECL method (Thermo Fisher).
2.5.3 Confocal Raman Configuration
The confocal Raman measurements were acquired at ambient conditions, in a
backscattering geometry, with an alpha300 R WITec system (WITec GmbH, Ulm,
Germany) using the 532 nm excitation of a frequency-doubled Nd:YAG laser. Alpha300 R WITec
system is shown in Figure 2.6. To avoid sample damage, the laser power was carefully kept at
values less than 5 mW. A 488-nm diameter single-mode optical fiber was used to couple the laser
beam into the microscope. The laser excitation, filtered by a holographic band-pass filter, was
collimated with a 100X objective lens with a numerical aperture (NA) of 0.90 (Olympus, Japan)
onto the sample surface. The scattered light collected with the same objective was first passed
through a holographic edge filter, and then optically guided using a 50 µm diameter multi-mode
optical fiber to a back-illuminated and VIS AR coated Marconi 40-11 CCD detector for data
recording. While the single-mode input optical fiber acts as a pinhole source for confocal
microscopy, the 50 µm multimode output optical fiber used to couple the collected Raman
scattering light to spectrometer functions as an entrance slit. An array of 150 × 150 Raman spectra
was recorded for all Raman images using an integration time of 50 ms per spectrum. The surface
Raman mapping images of independent cells were acquired with 25 µm × 25 µm scan sizes.
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Figure 2.6. Alpha300 R WITec Experimental Setup
The computer system setup with dual displays on the left portion of the figure consists of the alpha300 R WITec Control
Software and Analysis Package. The microscope system located above the vibrational-damping leveling platform
contains the alpha300 R WITec Raman microscope system.

2.5.3 Data Analysis Configuration
Raman background subtraction and spectral analysis was prototyped in C++11 combined
with the Qt cross-platform application framework. Final execution of code was completed in
MATLAB R2016a with backwards compatibility that was tested with MATLAB R2013a.
WITec’s Cluster Analysis package in the WITec Project Plus software accompanied the spectral
analysis of the data.
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CHAPTER 3: RESULTS AND DISCUSSIONS
3.1

Normal and Cancerous Breast Cell Distinction

With the current implementation of confocal Raman mapping through a raster-scanning
technique requiring relatively long acquisition times, several minutes for a complete map, the
potential of an in vivo application for clinical diagnosis is limited. However, by having a
collection of tens of thousands integrated Raman spectra available, it provides an excellent
avenue for a more detailed and accurate observation of morphological differences that exist
between non-tumorigenic breast epithelial cells and breast cancer cells from a research
perspective. Figure 3.1 depicts a visual comparison between the two integrated spectra of nontumorigenic breast epithelial cells (MCF-10A control sample cells; black line) and breast cancer
cells (MCF-7 control sample cells; red line). The comparison of the two integrated spectra show
a distinction between the cancerous and non-cancerous indicators through specific intensity
variations of vibrational lines, which is in agreement from related reports in literature [72]–[79].
Figure 3.1 contains a break between the 1900 cm-1 and 2500 cm-1 region, with a slight horizontal
axis change following the break for better accentuation and clarification of the areas of interest.
The MCF-7 integrated spectrum, as depicted by the red spectrum, was vertically shifted for
easier visualization and comparison towards the black, MCF-10A spectrum.
The first important factor to note is the lipid-protein profile that is predominant within the
2800 – 3000 cm-1 region. The MCF-7 cancerous spectrum has a significant increase in intensity
at the 2940 cm-1 Raman peak compared to the noncancerous region, by nearly a factor of two.
Contributions of charged amino acids, threonine, histidine, and proline aggregate, forming the
observed 2940 cm-1 Raman peak. Due to the influence of HER1/2 overexpression, a greater
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Figure 3.1. Integrated Raman spectra of MCF-10A and MCF-7 confocal Raman mappings
MCF-10A is the non-tumorigenic control sample in the black spectrum. MCF-7 is the breast cancer control sample
in the red spectrum. [85]

response is to be expected in the 2940 cm-1 Raman peak which has already been considered as
one indicator for carcinogenesis [76], [80]. Aromatic and aliphatic groups of amino acids can be
located at the 3055 cm-1 and 2870 cm-1 wavenumbers respectively, where there are no observable
differences in the integrated spectra. The broad region located around the 3358 cm-1 Raman peak
is slightly higher in intensity in the cancerous sample as compared to the noncancerous sample.
This region may be associated with the O-H stretching mode present in water [81], however
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Raman is known to not be highly sensitive to water absorption therefore this region is more
likely to be related to the N-H stretching mode of proteins and N-H stretching mode in DNA’s
nitrogenous bases [79]. Considering the increase in intensity located at the 1097 cm-1 and 1658
cm-1 wavenumbers, that are associated with DNA and protein content respectively, the increase
in the 3358 cm-1 region can be explained due to its relationship with DNA and proteins. Despite
the characterization of the 3385 cm-1 region is considered to be related with protein and DNA,
the potential contribution brought the adipose content within the same region should not be
ignored [81].
Following the observed responses of proteins that were briefly mentioned previously, it is
important to note the amide modes that are related with protein content and activity. The protein
modes in interest are Amide I and III located at 1658 cm-1 and 1240 cm-1 respectively [71], [82].
The Amide I signature located at 1658 cm-1 wavenumber, corresponds to the C=O stretching
mode in proteins, and there is a very distinct increase in intensity observed in the cancerous
sample in regards to the noncancerous sample. Amide III is located at the 1240 cm-1
wavenumber, is related to the C-N stretching and N-H bending modes, where a stark increase in
intensity is once again located in the cancerous sample, with only a slight response in the
noncancerous sample.
The lower region of the integrated spectra also shows some interesting remarks. The
noncancerous region shows a higher intensity response focused on the 752 cm-1 and 858 cm-1
wavenumbers which are almost not perceptible in the cancerous spectrum. In comparison
however, the cancerous spectrum contains a 784 cm-1 Raman peak that is absent in the
noncancerous spectrum. This change in peaks gives an interesting insight regarding the overall
DNA and RNA activity of the cell. The 752 cm-1 and 858 cm-1 wavenumbers correspond to DNA
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nucleic acids and collagen, whereas the 784 cm-1 wavenumber relates to both DNA and RNA
[71], [73], [82], [83]. This suggests that there is a dramatic reduction in collagen levels in
cancerous samples, due to the absence of the 858 cm-1 wavenumber, but also a significant
modification to DNA and RNA. This remark is further supported by the emergence of a weak
812 cm-1 peak in the cancerous sample that corresponds to the PO2- stretching mode in RNA
[73]. Furthermore, there is a significant influence of the 1097 cm-1 peak in the cancerous sample
which is associated to the PO2- stretching mode of DNA and RNA [73]. Another Raman
signature pair can be observed by the 752 cm-1 and 1587 cm-1 wavenumbers, which are both
associated to the ring breathing modes in DNA and RNA [73]. The two wavenumbers have an
observable influence in the noncancerous sample, but get severely diminished in the cancerous
sample. All the observed signature changes associated to DNA and RNA indicates that there is a
significant different in DNA/RNA characteristics between cancerous and noncancerous cells.
In addition to the difference of genetic and protein characteristics, investigations of the
cell’s surface should not be disregarded. A very weak vibration in the cancerous sample can
located at the 722 cm-1 wavenumber. This particular vibration is associated to the C-N bond
located in the quaternary ammonium groups of sphingomyelins and phosphatidylcholines, two
types of lipids that are major components of the cellular membrane [84]. Despite its weak
presence, the emergence of this wavenumber implies that there are membrane changes occurring
from noncancerous cells to cancerous cells that is associated with sphingomyelins and
phosphatidylcholines. Modifications towards these lipids have been reported in literature within
the lumen of cancerous breast ducts [74].
The other vibrational lines that depict a Raman response at 600 (broad), 940, 1010, 1320,
and 1460 cm-1 do not show any noticeable shifting or intensity modifications between the two
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samples. The broad band located at the 600 cm-1 wavenumber is associated towards
paraformaldehyde, which was used for cell fixation. All observed vibrational lines have their
assignments provided in Table 3.1 and are additionally marked with red (cancerous) and black
(noncancerous) arrows in Figure 3.1.
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Table 3.1. Assignments of vibrational modes for the Raman spectra acquired from MCF-7 and
MCF-10A cells
Wavenumber (cm-1)

Assignment

722

C-N symmetric (membrane phospholipid head)
stretching band/nucleotide peak symmetric
choline stretch, phospholipids, (H3C)N+
stretch band [86], [87]

752

DNA, nucleic acids, symmetric breathing of
tryptophan [75], [87]

784

DNA/RNA, pyrimidine bases of nucleic acids,
ring breathing of cytosine [75], [82], [88]

812

PO2- stretching mode of RNA [75]

858

C-C stretch proline ring in collagen [82]

1097

DNA, PO2- stretching mode [75]

1130

v(C-C) stretching vibration of lipids from
trans-segments and v(C-N) stretching vibration
of proteins [80], [87]

1240

Amide III, collagen [45], [87]

1320

(CH) deformation, guanine, CH3CH2 wagging
nucleic acids, CH3CH2 wagging collagen [45],
[87]
(CH2, CH3) asymmetric and symmetric
deformations of proteins [45], [82], [87]

1460
1587

Nucleic acids (guanine, adenine), Tryptophan
[75], [82], [87]

1658

Amide I in collagen (-helix), (C=O)
stretching mode of proteins [75], [82], [87]

2870

ν(CH2) stretching vibration of lipids [80]

2940

ν(CH3) asymmetric/symmetric, protein
aromatic and aliphatic amino acids [80]

3358

O-H stretching mode of water, N-H stretching
vibration of DNA and protein [79], [80], [88]
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3.2

EGF Responsive Breast Cell Cancer Distinction
Concluding cancerous and noncancerous breast cell distinction, the dominant indicators

of the cellular status is mostly attributed to DNA/RNA and protein characteristics. Considering
the overall survival of breast cancer patients following early cancer treatment, accurate detection
of both the cancer and the cancer’s characteristics could very well make the difference of a
patient’s outcome. Considering the scenario in which not only cancer detection was established,
but the type of cancer is also determined, the patient’s survival outlook can approach onehundred percent survival with targeted therapy. We have considered this by having a qualitative
investigation between untreated and treated MCF-7 cancer cells using epidermal growth factor
(EGF). EGF is a known cellular proliferation factor that can instigate HER1/2 associated breast
cancer. MCF-7 cells were used for this experiment due to their sensitivity and response towards
the EGF ligand. In Figure 3.2, we provide a visual mapping of the previous mentioned biological
constituents through surface confocal Raman mapping. This provides a high acuity of the
location, distribution, and activity of the biological constituents within the cells. Pseudo-coloring
was used to provide a visual determination of Raman intensity, where bright yellow indicates
high intensity and dark orange indicates low intensity.
Figure 3.2a and 3.2b indicate the accumulation of the nucleic-associated 784 cm-1
signature that, not only depicting the cellular nucleic region, but the potential snapshot of the
anaphase portion of a cell’s division cycle in Figure 3.2a. This observation is given by the
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Figure 3.2. Confocal Raman mapping images of vibrational signatures from untreated and EGF-treated MCF-7
Cells
Figures (a, c, e, g) correspond to the untreated MCF-7 cell and Figures (b, d, f, h) correspond to the EGF-treated
MCF-7 cell. Figures (a, b) corresponds to DNA/RNA. Figures (c, d) corresponds to the cumulative distribution
of 1240 and 1658 cm-1 protein signatures. Figures (e, f) corresponds to the 2940 cm-1 protein response. Figures
(g, h) corresponds to the lipid band feature at 2870 cm-1. Brighter pseudo-colors correspond to higher intensity.
Arrows in Figure (e) indicate differences from the presented Figure (c). [85]

observable dual centromeres providing two deposits of high-intensity signatures in the left and
right regions of the cell. Figures 3.2c and 3.2d provide the accumulative distribution of the 1240
and 1658 cm-1 protein signatures. There were no easily comparable differences between the two
images, however the imaging is provided as a comparison point for the next series of mapped
Raman features. Figures 3.2e and 3.2f provide a mapping of the 2940 cm-1 vibration which looks
remarkably similar to the previous set of mappings in figures 3.2c and 3.2d. However, acute
observation reveals differences between figures 3.2c and 3.2e, which are marked in the white
arrows in figure 3.2e. Focusing on the differences that were revealed, through discrimination
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focusing around the 2870 cm-1 lipid signature, as depicted in figures 3.2g and 3.2h, confirms the
presence marked by the white arrows in figure 3.2e. Through this, we are able to see the rise of a
specific lipid-related protein response occurring, which indicates the presence of a close
relationship between lipid and protein signatures.
Utilization of advanced background subtraction and enhancing algorithms developed
with confocal Raman mapping in mind, we are able to provide single-band enhancement from
the Raman mapping data. An alternative to Figures 3.2c-h is provided in Figure 3.3 where the
images were conducted through the custom algorithm. Figure 3.3 provides a harsh discrimination
of intensity responses, allowing us to not only visually see specifically the highest contributing
locations within a cell for that particular band, but also providing a relatively higher resolution
snapshot of the cell for that particular. The algorithm used in Figure 3.2 does not allow for such
harsh discrimination to occur, but allows an overall picture of the bands in comparison with the
rest of the cell’s structure. Together, we are given two slightly different perspectives of the same
biological constituents present with the cells. Due to the higher discrimination and accentuation
of wavenumbers, we are able to observe specific lipid-protein responses in the EGF treated
sample that was earlier depicted in the untreated sample. These particular responses are indicated
with white arrows in figure 3.3h, showing differences from figures 3.3b and 3.3d.
The importance of cytoplasmic lipid droplets within cancerous cells and tissues has been
recently emphasized in literature due to the metabolic resources it provides for the rapidly
proliferating cell. It was noted that the altered cellular processes can result in enhanced
lipoprotein metabolism that is associated with modified lipogenic enzyme activity throughout all
stages of cellular regulation and proliferation [75], [89]. Not only has the generation, and usage,
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Figure 3.3. In-House algorithmic processing of confocal Raman mapping data of vibrational signatures from
untreated and EGF-treated MCF-7 Cells
Figures (a, c, e, g) correspond to the untreated MCF-7 cell and Figures (b, d, f, h) correspond to the EGF-treated
MCF-7 cell. Figures (a, b) corresponds to the 1240 cm-1 protein signature. Figures (c, d) corresponds to the 1658
cm-1 protein signature. Figures (e, f) corresponds to the 2940 cm-1 protein response. Figures (g, h) corresponds to
the lipid band feature at 2870 cm-1. Brighter pseudo-colors correspond to higher intensity. Arrows in Figure (h)
indicate differences presented in Figures (b,c).

of this lipid reservoir been shown to contribute towards cancer proliferation [74], it has also
indicated the stimulation of cellular mobility [89]. Figures 3.2g, 3.2h, 3.3f, and 3.3h indicate a
good agreement regarding activity of lipid and lipoprotein metabolism, additionally when
observing the differences between the untreated and treated MCF-7 cells, with the treated MCF-7
cell having an overall higher expression and intensity of lipid related vibrations. Additionally,
this explains the emergence of the 722 cm-1 signature as well as the doubling of the 2940 cm-1
peak within the cancerous integrated spectrum presented in figure 3.1. Furthermore, as depicted
by the white arrows in both figures 3.2 and 3.3, the increase of activity is located closer to the
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cell membrane which further emphasizes the contribution of lipid synthesis and metabolism
within tumorigenic cell populations.
For better deconstruction and distribution of lower wavenumber associated constituents,
those related with DNA/RNA components, the cluster analysis software suite within the WITec
Project Plus package was utilized. The cluster mapping data is presented in Figure 3.4a and 3.4b,
showing comparative confocal Raman mappings between the untreated and EGF-treated
samples. Providing an understanding of spectroscopic data within the micro-scale regions, the
graphs presented in figures 3.4c and 3.4d are associated with each cluster with a uniform color
coding scheme maintained throughout.
The first comparison to be discussed is the close similarity between figure 3.4a and 3.2a,
verifying the accuracy of the calculation regarding DNA/RNA constituents. The second
comparison of note is between figures 3.4a and 3.4b, which shows a significant increase of the
red region for the EGF-treated cell in comparison to the untreated cell. The increase is rather
substantial with the red region of the untreated cell occupying about 20% of the image, whereas
a staggering 80% of the treated cell image is occupied by the combined red and green region.
The explanation for the treated cell having a green region, instead of being purely red, is due to
the discrimination of two specific vibrational responses that was be expanded in more detail later
on. To understand why there is such a significant difference in distribution and intensity of
DNA/RNA signal, it is crucial to take a detailed look in the provided spectra in figure 3.4c. The
dominant feature within the blue spectrum is the 752 cm-1 wavenumber. This band steadily
decreases within the green spectrum, where the emergence of the 784 cm-1 wavenumber
contributes to the cluster. In the red spectrum, the 784 cm-1 wavenumber reigns dominant with
the 752 cm-1 peak being mostly extinguished. Throughout this journey, there is an emergence of
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Figure 3.4. Cluster analysis of confocal Raman mapping images from untreated and EGF-treated MCF-7 cells
Figures (a, b) are confocal Raman mapping images processed through the Cluster analysis software in the WITec
software analysis suite for untreated and EGF-treated MCF-7 samples respectively. Figures (c, d) correspond to
the Raman spectra from each cluster and are focused only in regions of interest. Uniform color code is
maintained between all Figures (a, b, c, d). [85]

two completely new peaks, 920 cm-1 and 1185 cm-1, which are assigned to phosphorylated
threonine and serine respectively [90]. These two wavenumbers are marked with black arrows in
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the spectra for greater visibility. The combined emergence of these two wavenumbers suggest
the presence of a phosphorylation process that can serve as a means for enhanced proliferation
in EGF-treated cells, as evidence by the requirement of threonine and serine site activation for
this mechanism [90], [91]. Further validity for this assumption is supported by Western blot
analysis which is displayed in figure 3.5. Additionally, a significant decrease of collagen content,
as evidenced by the 858 cm-1 wavenumber, is seen when traversing from the blue to green to red
regions. Furthermore, changes in intensity in the 1320 and 1350 cm-1 peaks are observed but
there is no particular trend in these changes, besides the slight increase in the 1350 cm-1 peak
within the red spectrum, suggesting another site of DNA modification. For the protein specific
bands located at 1010 cm-1, 1240 cm-1, 1460 cm-1, 1587 cm-1, and 1658 cm-1, no observable
intensity changes have occurred. Lastly, the far-wavenumber region of lipids and proteins, the
2800-2900 cm-1 region and 2940 cm-1 region respectively, also have reports of no observable
modifications.
Verification of the EGF activity within the cancer cells was conducted through a Western
blot analysis which can be viewed in figure 3.5. The addition of EGF (100 ng/mL) to the MCF-7
cells resulted with the appearance of phosphorylated p44 MAPK (Erk ½ (Thr202/Thr204)) and
phosphorylated Akt (Ser473) regardless of the type of lysis buffer employed. The contribution of
this data confirms that the presence of the EGF ligand leads to the instigation of several
phosphorylation events associated to the known EGF response pathway. With the presence of
phosphorylated p44 MAPK and Akt, the Western blot analysis strongly agrees with the
emergence of the 920 cm-1 and 1185 cm-1 peaks within figure 3.4c.

44

Figure 3.5. Western blotting analysis of EGF stimulation of MCF-7 cells.
The cells were starved for 24 hours prior to EGF exposure for 30 minutes and at a
concentration of 100ng/mL, then harvested with 3 different lysis buffers using BD Falcon cell
scrapers. The #1 lysis buffer refers to RIPA-like, #2 to NP-40, and #3 to MILLIPLEX MAP for
multiplexing. The cells under the control treatment were only treated with RPMI basal
media. Amido black staining of the membrane (bottom) indicates even transfer of proteins,
and the membrane was probed for phosphorylated p44 MAPK, and phosphor-Akt. Betaactin was used as an additional loading control. [85]
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CHAPTER 4: CONCLUDING REMARKS
Through the utilization of confocal Raman spectroscopy in conjunction with algorithmic
methods for data clarification and enhancement, we were able to verify and evaluate EGFR
activity in tumor cells through label-free means. Specification of EGF-related activity can
provide specific Raman-guided breast tumor diagnosis, that can serve as an advantageous step
towards the treatment of this disease. The steps taken in this study confirm that Raman
spectroscopy can indeed discriminate tumorous breast cancer cells from nontumorous cells. This
data was apparent within the observable modifications and changes that occur in associated
DNA/RNA and protein characteristics. However, we decided to ask the following question to
ourselves: we are able to determine tumorous from nontumorous cells, but can we also determine
tumorous from other tumorous cells? Our steps in answering this question brought us to the
comparison of MCF-7 cells instigated by EGF ligands, and MCF-7 cells in the absence of such
ligands. The results under these conditions show that we were indeed able to generate distinct
Raman profiles depending on the activity of EGF. Not only are modifications observable in the
lipid constituents and DNA/RNA contents of the cell, but the emergence of previously unseen
vibrations in phosphorylated threonine and serine became apparent. These findings were in good
agreement with the following Western blotting analysis results, in which the addition of EGF to
MCF-7 cells leads to downstream molecular phosphorylation within the EGFR pathway.
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